AllSci News
Frontier Biotech and GSK sign USD 1b. exclusive licensing deal for siRNA kidney disease therapies
Frontier Biotechnologies Inc., a Nanjing, China-headquartered biopharma company, announced an exclusive licensing agreement with GSK, the London-based...
Idorsia's daridorexant shows positive Phase II results in pediatric insomnia disorder study
Idorsia Ltd, based in Allschwil, Switzerland, reported positive top-line results from a Phase II dose-finding study of daridorexant in pediatric patients...
Unnatural Products and Novartis sign USD 1.8b macrocyclic peptide deal for cardiovascular disease
Unnatural Products, Inc. (UNP), a privately held biotechnology company headquartered in Santa Cruz, California, announced a research collaboration and...
FDA approves Denali Therapeutics' Avlayah for neurologic symptoms of Hunter syndrome in pediatric patients
The US FDA has granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy developed by Denali Therapeutics for the...
Kymera Therapeutics Advances KT-579 IRF5 Degrader Into Phase 1 Trial for Autoimmune Disease
Kymera Therapeutics has begun dosing participants in the first-ever clinical study of a drug designed to destroy interferon regulatory factor 5, a...
China's NMPA approves Xdemvy for Demodex blepharitis, triggering $15M milestone payment to Tarsus
China's National Medical Products Administration has approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis, making...
Inhibikase's IB-001: First-in-Human Phase 1 Trial Targets Chronic Hepatitis B Treatment
A Novel Approach to Chronic Hepatitis B: Inside Inhibikase's First-in-Human IB-001 Trial
Asahi Kasei Acquires Aicuris Anti-infective Cures for EUR 780m to Bolster Infectious Disease Portfolio
The Asahi Kasei Aicuris acquisition, announced on February 26, 2026, will see the Tokyo-based conglomerate pay approximately EUR 780 million (USD 919...
Excalipoint Therapeutics Closes Oversubscribed $68.7 Million Seed Round for T-Cell Engager Therapies
Excalipoint Therapeutics, a Shanghai-based biotechnology company focused on next-generation T-cell engager therapies for cancer and autoimmune diseases, has...
FDA Approves Tecvayli Plus Darzalex Faspro for Relapsed or Refractory Multiple Myeloma
The US FDA has approved Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adults...
AnnJi Pharmaceutical's AJ201 Secures US FDA Fast Track Designation for Kennedy's Disease Treatment
FDA Grants Fast Track Designation to Promising Kennedy's Disease Treatment
Affinia Therapeutics Secures FDA Fast Track Designation for BAG3 Dilated Cardiomyopathy Gene Therapy AFTX-201
Affinia Therapeutics, a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, announced that the U.S. Food and Drug Administration...
Japan approves Viatris' Effexor as first pharmacological treatment for generalized anxiety disorder
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor (venlafaxine hydrochloride) for the treatment of adults with generalized anxiety...
GelMEDIX Closes $13M Seed Round, Partners With Global Pharma on Hydrogel Stem Cell Therapies
GelMEDIX, Inc., a privately held biotechnology company based in Cambridge, Massachusetts, announced the completion of a $13 million seed financing round...
Sensorion pushes AAV gene therapy targeting connexin 26 mutations toward clinic for most common genetic deafness
Sensorion, a French clinical-stage biotechnology company, announced on March 23, 2026, that it is advancing SENS-601 (GJB2-GT), an AAV-based gene therapy...
The AllSci Brief
Systematic R&D and deal news. Daily.